One analyst applauded Trump’s order as an “official stamp of validation” for psychedelics.

President Donald Trump signed an executive order Saturday to accelerate research for some psychedelic drugs to treat mental health disorders.

President signed executive order directing FDA to expedite review of psychedelic drugs including ibogaine

One analyst applauded Trump’s order as an “official stamp of validation” for psychedelics.

Some psychedelic stocks can rally after the executive order on the use of the this type of drug for mental health, Oppenheimer said.

The White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and ibogaine.